TABLE 3.

Antibiotic therapy of 416 Staphylococcus aureus bacteremia episodes, by study period

Variable, n (%)	Preimplementation (n = 176)a	Postimplementation (n = 240)b	P value
Initial antistaphylococcal therapyc
Vancomycin	133 (76)	197 (82)	0.11
Daptomycin	5 (3)	2 (1)	0.12
Linezolid	8 (5)	13 (5)	0.69
Ceftaroline	2 (1)	4 (2)	0.65
Cefazolin	2 (1)	7 (3)	0.31
Ceftriaxone	11 (6)	14 (6)	0.86
Antistaphylococcal penicillin	2 (1)	6 (3)	0.48
No antibiotics	0 (0)	2 (1)	0.34
Definitive antibiotic therapyd
Vancomycin	61 (35)	52 (22)	0.003
Daptomycin	19 (11)	36 (15)	0.21
Linezolid	2 (1)	11 (5)	0.05
Ceftaroline	11 (6)	33 (14)	0.01
Cefazolin	27 (14)	58 (24)	0.027
Ceftriaxone	41 (23)	38 (16)	0.055
Antistaphylococcal penicillin	21 (12)	47 (20)	0.037
Combination antistaphylococcal therapy	11 (6)	38 (16)	0.003
Daptomycin-ceftaroline	6 (3)	23 (10)	0.02
Vancomycin-ceftaroline	2 (1)	5 (2)	0.7
Vancomycin-β-lactams	2 (1)	10 (4)	0.08
Other combinations	1 (1)	0 (0)	0.23
Recommended treatment duration, wks, median (IQR)	6 (4–6)	6 (4–6)	0.32

^aPreimplementation period from 1 January 2018 to 13 January 2019.

^bPostimplementation period from 14 January 2019 to 31 December 2019.

^cAntibiotic therapy within the day of index blood culture.

^dAntibiotic therapy at discharge or final infectious diseases recommendations.